갈렉틴 테라퓨틱스(GALT)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $3.89 (+4.85%), 시가총액 $0.14B, 52주 최저~최고 $1.24 ~ $6.51.
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in drug development to create new therapies for fibrotic disease and cancer. The company's lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in a Phase 2 clinical study in MASH patients with advanced fibrosis and a second Phase 2b clinical trial in MASH patients with compensated cirrhosis and portal hypertension. It has a joint venture co-owned by SBH Sciences, Inc. to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics Inc. in May 2011
갈렉틴 테라퓨틱스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
갈렉틴 테라퓨틱스의 현재 주가는 $3.89 (+4.85%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
갈렉틴 테라퓨틱스의 시가총액은 약 $0.14B입니다.
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in drug development to create new therapies for fibrotic disease and cancer. The company's lead product candidate is bel